Similar Papers

Paper Title
Journal
Date
Author
Cariprazine vs risperidone efficacy on predominant negative symptoms of schizophrenia: Post hoc analysis of negative symptoms subdomains
Agota Barabassy
-
Agota BarabassyAgota Barabassy
21 Aug 2017
Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial
György Németh ... W Wolfgang Fleischhacker
The Lancet | VOL. 389
György Németh, et. al.György Németh ... W Wolfgang Fleischhacker
07 Feb 2017
A review on the pharmacology of cariprazine and its role in the treatment of negative symptoms of schizophrenia.
Panneer Selvan ... Chittaranjan Andrade
Frontiers in Psychiatry | VOL. 15
Panneer Selvan, et. al.Panneer Selvan ... Chittaranjan Andrade
22 Apr 2024
Bitopertin in Negative Symptoms of Schizophrenia—Results From the Phase III FlashLyte and DayLyte Studies
Dragana Bugarski-Kirola ... Stephen R Marder
Biological Psychiatry | VOL. 82
Dragana Bugarski-Kirola, et. al.Dragana Bugarski-Kirola ... Stephen R Marder
15 Dec 2016
View more papers

More From: European Neuropsychopharmacology

Paper Title
Journal
Date
Author
Therapeutic potential of minor cannabinoids in psychiatric disorders: A systematic review
Guido Cammà ... Albert Batalla
European Neuropsychopharmacology | VOL. 91
Guido Cammà, et. al.Guido Cammà ... Albert Batalla
01 Feb 2025
Editorial Board
-
European Neuropsychopharmacology | VOL. -
--
01 Feb 2025
Valproate's impact on future generations — A call for stricter guidelines for maternal and paternal use
Meritxell González-Campos ... Gerard Anmella
European Neuropsychopharmacology | VOL. 91
Meritxell González-Campos, et. al.Meritxell González-Campos ... Gerard Anmella
01 Feb 2025
Examining the Impact of Comorbid Posttraumatic Stress Disorder on Ketamine's Real-World Effectiveness in Treatment-Resistant Depression
Danica E Johnson ... Joshua D Rosenblat
European Neuropsychopharmacology | VOL. 91
Danica E Johnson, et. al.Danica E Johnson ... Joshua D Rosenblat
01 Feb 2025
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.